Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 21OTHER_GOV 1NIH 1NETWORK 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Neoplasms 1

Interventions

pembrolizumab 1033Carboplatin 971Paclitaxel 942Gemcitabine 799Cisplatin 757Docetaxel 698Bevacizumab 637Nivolumab 520Pemetrexed 507Capecitabine 475Cyclophosphamide 473Fluorouracil 425Dexamethasone 410Rituximab 391Oxaliplatin 352Injections 347Trastuzumab 313atezolizumab 312Cetuximab 291Leucovorin 290Irinotecan 271130-nm albumin-bound paclitaxel 257Prednisone 251Ipilimumab 244Doxorubicin 241Lenalidomide 231Fulvestrant 226fludarabine 219durvalumab 211Erlotinib Hydrochloride 196

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Anti-Bacterial Agents × Clear all
NCT02366884 2022-04-06

Clinical Evaluation of a New Form of Cancer Therapy (Atavistic Chemotherapy) Based on the Principles of Atavistic Metamorphosis (2011)

Dr. Frank Arguello Cancer Clinic

Phase 2 Unknown
250 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡